What is the 13F Pro Quality Score for HURA?

13F Pro ranks TuHURA Biosciences, Inc./NV (HURA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HURA's current score at https://13fpro.ai/company/HURA (free sign-up required for the full ranking).

Which hedge funds own the most HURA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of HURA include VANGUARD CAPITAL MANAGEMENT, NORTHERN, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/HURA as soon as new 13F filings post.

Where does 13F Pro source HURA data?

All TuHURA Biosciences, Inc./NV fundamentals and ownership data come directly from SEC EDGAR. TuHURA Biosciences, Inc./NV files with the SEC under CIK 1498382. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HURA in?

TuHURA Biosciences, Inc./NV (HURA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HURA research updated on 13F Pro?

HURA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TuHURA Biosciences, Inc./NV(HURA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1498382 HURA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

HURA Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for TuHURA Biosciences, Inc./NV (HURA), a Healthcare sector company. HURA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of HURA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, NORTHERN, BlackRock, based on the most recent SEC filings. HURA trades on the Nasdaq exchange and files with the SEC under CIK 1498382. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TuHURA Biosciences, Inc./NV directly from SEC EDGAR.

✦

Fun facts about TuHURA Biosciences, Inc./NV

Quirks, history, and lore behind HURA — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · micro-cap · incorporated in Nevada · operating in the healthcare sector.
2
The Numbers
With no product revenue yet, this early-stage company runs on capital raises — a classic pre-commercial biotech burn rate. Think small team, big ambitions.
3
The History
A relatively recent entrant to public markets, it entered the biotech space during a wave of small companies chasing cancer immunology breakthroughs.
4
The Secret
Its pipeline targets tumor microenvironment biology — the idea that tumors build a kind of immune-suppressing force field that drugs need to crack.
5
The Lore
The company's name nods to a radiant, luminous concept — fitting for a firm betting it can shine a light on some of oncology's darkest corners.
6
The Giveaway
Ticker HURA · focused on cancer immunotherapy · and named with a word that sounds like it belongs at a victory celebration.

▶ Think you know your stocks? Play the Daily Ticker

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

—FY 2026

FY23 $-14.6MFY24 $-8.3MFY25 —FY26 —

Total Assets

-8.3% YoY

$31.7MFY 2026

FY23 $4.0MFY24 $6.2MFY25 $34.6MFY26 $31.7M

Total Debt

$3.6MFY 2026

FY23 —FY24 —FY25 —FY26 $3.6M

Op. Cash Flow

—FY 2026

FY23 $-11.9MFY24 $-7.2MFY25 —FY26 —

Free Cash Flow

—FY 2026

FY23 —FY24 —FY25 —FY26 —

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Income	—	—	$-8.3M +43.2%	$-14.6M +35.4%	$-22.7M +40.8%	$-38.3M
Total Assets	$31.7M -8.3%	$34.6M +458.2%	$6.2M +55.9%	$4.0M -75.1%	$15.9M +17.8%	$13.5M
Total Debt	$3.6M	—	—	—	—	—
Operating Cash Flow	—	—	$-7.2M +39.5%	$-11.9M +41.8%	$-20.4M -8.1%	$-18.9M
Free Cash Flow	—	—	—	—	$-20.6M	—

Get alerted when HURA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TuHURA Biosciences, Inc./NV including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HURA

VANGUARD CAPITAL MANAGEMENT LLC
$5.3M2,267,901 sh
NORTHERN TRUST CORP
$3.8M1,621,042 sh
BlackRock, Inc.
$1.6M690,088 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.1M484,219 sh
MILLENNIUM MANAGEMENT LLC
$1.1M454,535 sh
AQR CAPITAL MANAGEMENT LLC
$993.6K424,600 sh
VANGUARD FIDUCIARY TRUST CO
$587.8K251,186 sh
CITADEL ADVISORS LLC
$543.6K232,319 sh
STATE STREET CORP
$440.9K188,404 sh
JANE STREET GROUP, LLC
$383.5K163,891 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$5.3M	2,267,901
NORTHERN TRUST CORP	$3.8M	1,621,042
BlackRock, Inc.	$1.6M	690,088
GEODE CAPITAL MANAGEMENT, LLC	$1.1M	484,219
MILLENNIUM MANAGEMENT LLC	$1.1M	454,535
AQR CAPITAL MANAGEMENT LLC	$993.6K	424,600
VANGUARD FIDUCIARY TRUST CO	$587.8K	251,186
CITADEL ADVISORS LLC	$543.6K	232,319
STATE STREET CORP	$440.9K	188,404
JANE STREET GROUP, LLC	$383.5K	163,891

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HURA on your watchlist

Track score changes the day TuHURA Biosciences, Inc./NV files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HURA a good stock to buy?

13F Pro's AI-powered analysis of TuHURA Biosciences, Inc./NV (HURA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HURA are available on the HURA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HURA is classified as a small company.

Which hedge funds own HURA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HURA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TuHURA Biosciences, Inc./NV's investment landscape.